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Abstract: Molecular ultrasound imaging or targeted contrast-enhanced ultrasound (CEUS) is a relatively new technique that
has varied applications to augment both diagnostics and therapeutics. Ultrasound contrast agents are conjugated to ligands
that bind with specific biomarkers in the areas of interest which can then be quantified using ultrasound technology. This
technique has numerous clinical applications including studying pathophysiology of disease, improving diagnostic sensitivity
and specificity, and improving localized drug delivery. This technology, most notably, has proven useful in numerous oncologic
and cardiovascular applications. Given ultrasound’s advantages over other radiographic studies including its low cost, lack of
ionizing radiation, portability, ability to provide real-time imaging, and non-invasiveness, recent investigations have expanded
the utility of molecular ultrasound. In this review, we briefly review targeted ultrasound contrast agents and explore the current
applications of molecular ultrasound as well as future applications based on the currently published literature.
Key words: Molecular ultrasound imaging; Contrast-enhanced ultrasound; Therapeutics; Contrast media
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M

olecular ultrasound imaging or targeted
contrast-enhanced ultrasound (CEUS) is a
relatively novel technique that combines
the use of ultrasound contrast agents conjugated to
ligands that bind with specific biomarkers in the areas
of interest. These agents can accumulate at their target
passively (attachment of the shell of the contrast agent
to cells) or actively (modification to the shell to allow
attachment to specific ligands). Once administered, the
contrast agent with the specific ligand accumulates in
the area with the highest affinity to the target molecule
(small proteins, antibodies, etc.). Ultrasound technology
allows quantitative detection of expression of the target
molecule which allows a wide scope of diagnostic and
therapeutic applications of molecular ultrasound. The
promising utility of targeted CEUS combined with
the relative convenience of using ultrasound including
its low cost, lack of ionizing radiation, portability,
real-time imaging, and non-invasiveness, makes this
technology ideal to also explore the pathophysiology

of certain diseases, particularly in the cardiovascular
field. The most beneficial application of CEUS and nonnephrotoxic ultrasound contrast agents is when computed
tomography (CT) and magnetic resonance imaging (MRI)
are contraindicated [1,2].
The contrast agents used for targeted CEUS can
be divided into two main categories, microbubble and
non-microbubble, each of which have its own unique
applications. Microbubbles consist of a gas core encased
by a hard shell which can be composed of various
materials including sugars, proteins, polymers, and lipids
(Fig. 1). The shell prevents gas diffusion and, by adding
a polyethylene glycol component, reduces aggregation.
Different gases have been used for the core component
of the microbubble, of which heavier, biologically inert
gases are more stable and circulate longer intravascularly.
Microbubbles are typically 1 to 6 µm in diameter, thus
usually contained within the vascular space. This makes
microbubbles ideal for intravascular imaging rather than
imaging extravascular components [1,2].
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Non-microbubble contrast agents are generally
smaller than microbubble contrast agents (10-1000 nm)
and are therefore better at entering the extravascular
space (Fig. 2). One major disadvantage of these contrast
agents is the poor acoustic reflectivity of the liquid or
solid colloid core due to its small size and incompressible
nature, making imaging with ultrasound difficult.
To optimize visualization, different formulations
of these contrast agents have been synthesized. An
example of this is vaporization of the liquid core of a
perfluorocarbon (PFC) nanodroplet into gas to increase
ultrasound detection. Non-microbubble contrast agents
are particularly useful in drug delivery due to its ability
to enter the extravascular space. When nanobubbles, for
example, are exposed to ultrasound acoustic waves after
aggregating in the target in the extravascular space, they
release chemotherapeutic agents in tumors [1,2].
Abtibody that binds
to antigen on cell
surface

Gas Core

Shell

Biotin-avidin
bridge and spacer
complex attached
to the lipid layer of
the shell

Figure 1 Illustration of a targeted microbubble complex composed of
microbubble with gas core linked to antibody by a biotin-avidin and spacer
complex.

Hydrophilic drug
Hydrophilic drug
Aqueous Core

Gas bubble
Lipid bilayer

Figure 2 Illustration of a drug-loaded liposome with an aqueous core and
gas bubbles in the lipid bilayer (can also be confined within the inner lipid
layer in the same component as the aqueous core). Hydrophilic drugs can
be loaded within the aqueous core and hydrophobic drugs can be loaded
within the lipid bilayer.

There are multiple recent literature reviews
discussing contrast agents. Chong’s review on the
current and future applications of ultrasound contrast
agents explored contrast agents targeting molecules
such as vascular endothelial growth factor receptor
2 (VEGFR2) and alpha-v beta-3 (avb3) and the first
agent in human clinical trials, BR55 [3]. These targets
have been utilized in many recent studies to evaluate
AUDT 2019;03:062–075

neoplastic angiogenesis and drug or gene therapy for
cancer. New advancements in technology including
superharmonic ultrasound, high frame rate, and superresolution ultrasound are also discussed, all of which
could potentially provide higher resolution images [3].
Guvener’s review of applications of ultrasound contrast
agents similarly discussed the above applications as well
as recent advancements such as drug delivery through the
blood-brain barrier [4]. Wang’s review of microbubbles
discusses the current microbubble design trend and
notably reviews current microbubbles in clinical trials
or clinical usage including Sonazoid which shows
promise in liver cancer monitoring and image-guided
procedures and BR55 which continues to be explored
in detecting and monitoring malignancies in multiple
organs [5]. Zlitni’s concise review discusses BR55 and
recent applications of nano-sized contrast agents [6].
As reviewed in these recent papers, there are multiple
promising and unique applications of ultrasound contrast
agents.
This review will discuss advancements in the
literature of current potential human applications of
molecular ultrasound, and future potential applications of
molecular ultrasound as demonstrated in animal models.

Oncological Applications
Breast
There have been multiple advancements in molecular
targets for breast cancer imaging. The most established
contrast agent, BR55 (MDKDR, Bracco Suisse), was
used in a study to explore early breast cancer detection
via VEGFR2 expression. The study was conducted using
breast cancer xenografts in mice and found that VEGFR2
expression decreased with tumor growth but expression
was still detectable with imaging. Using BR55 targeting
VEGFR2 to detect early angiogenesis is a promising
modality for breast cancer detection [7]. A later firstin-human study using the BR55 targeting kinase insert
domain receptor (KDR) in breast and ovarian lesions
found good correlation of KDR expression with
immunohistochemistry (IHC) without safety concerns
about BR55, establishing the promising use of this
contrast agent in targeting malignant breast and ovarian
lesions [8].
Other contrast agents and molecular targets have been
studied in animal models. Wilson and Bachawal explored
with use of B7-H3 (CD276) as a target for breast cancer
detection and found strong correlation with IHC [9,10].
A later study by Wilson and Bachawal found that this
molecular target can detect disease status (DCIS and
invasive carcinoma versus normal or hyperplastic tissue)
with high sensitivity and specificity [11].
063
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Hydrophilic drugs can be loaded within the aqueous core and hydrophobic drugs can be loade
lipid bilayer.

Multiple researchers in the past few years have created
novel contrast agents conjugated to different ligands to
image breast cancer in animal models. Abou-Elkacem
engineered a new fibronectin scaffold ligand attached to
microbubbles that targets VEGFR2 in breast cancer and
found significantly increased binding to breast cancer
tissue versus normal tissue. Since this novel ligand is
small and lacks disulfide bonds and glycosylation, it can
be cheaper and produced more efficiently [12]. Jiang
engineered a new Herceptin-targeted nanobubble contrast
agent (NBs-Her) for patients with HER-2 positive breast
cancer. This contrast agent with Her ligand has greater
half life and tumor specificity that could also potentially

make it useful for therapy [13] (Fig. 3). Li created
fluorescent nanobubbles conjugated to PNBL-NPY ligand
to target Y1 receptors for breast cancer imaging [14]. Du
created a perfluoropropane (C3 F8)-filled poly(lactic-coglycolic acid) (PLGA) nanobubble that targets both HER2 and VEGFR2 which may enhance ultrasound images
due to its dual-targeting capability [15]. Xu explored
the dual-targeting capability of this novel contrast agent
further and found that dual-targeted agent had more
intense signal than single-targeted agent [16]. Wischhusen
created netrin-1 microbubbles as a potential diagnostic
and therapeutic marker for interference therapy in breast
cancer [17].

0 min         1 min          30 min         40 min

MDA-MN-231+NBs-Her
A

MDA-MN-231+NBs-Blank
B

SK-BR-3+NBs-Her
C

SK-BR-3+NBs-Blank
D
Figure 3 In vivo tumor targeting. Images were taken at the indicated time points (0, 1, 30, and 40 min) after nanobubbles were injected into the
transplanted SK-BR-3 tumors injected with Herceptin-conjugated nanobubbles (NBs-Her; A) or unconjugated nanobubbles (NBs-Blank; B) and in the
transplanted MDA-MB-231 tumors injected with NBs-Her (C) or NBs-Blank (D) (Reprinted with permission from reference [13])

Figure 3 In vivo tumor targeting. Images were taken at the indicated time points (0, 1, 30, and
after nanobubbles were injected into the transplanted SK-BR-3 tumors injected with Herceptin
conjugated nanobubbles (NBs-Her; a) or-integrin
unconjugated
nanobubbles (NBs-Blank; b) and in the
As seen in the above studies, there have been
expression using microbubbles [18,19]. As
MDA-MB-231
with
NBs-Her
(c)theorfirst
NBs-Blank
(d) to(Reprinted
w
discussed
above,
BR55 is
contrast agent
be
numerous transplanted
new advancements
in moleculartumors
targetsinjected
and contrast
agents as well
their applications
permission
fromasreference
[13]) for explored in humans. Smeenage investigated the safety
identifying breast cancer earlier and treating breast
cancer more effectively. The potential clinical application
of the BR55 contrast agent is promising since it has
shown some success in clinical trials, but future studies
can also explore further applications of this contrast
agent and human application of more novel contrast
agents.

Prostate
Most molecular imaging studies in prostate cancer
focused on angiogenesis evaluation and new molecular
targets for therapy. Early studies explored VEGFR2,
intracellular adhesion molecular-1 (ICAM-1), and αvβ3
064

and feasibility of this agent in targeting VEGFR2 and
found that patients with prostate cancer had detectable
levels of BR55 which can be utilized in further studies
with further fine-tuning of doses to determine clinical
significance [20].
A new ligand was investigated in the recent literature
to detect prostate cancer which may improve current
limitations with imaging specificity. Anti-prostate
specific membrane antigen (PMSA) A10-3.2 aptamer
was created and conjugated with nanobubbles to target
and accumulate in PMSA positive cells in mice with
prostate cancer xenografts [21]. In another study,
porphyrin-grafted lipid (PGL) microbubbles were created

Thumar et al. Applications in molecular ultrasound imaging

to attempt photodynamic therapy (PDT) for prostate
cancer. To improve some limitations of visualizing
target lesions with conventional ultrasound, molecular

ultrasound using these contrast agents improved
visualization and targeting which subsequently helped
administer photodynamic therapy [22] (Fig. 4 and 5).

A

B
Figure 4 Schematic of the microbubble-based, ultrasound-assisted PDT strategy. (A) Preparation of PGL-MB and its transformation from microbubbles
to nanoparticles under exposure to low-frequency ultrasound (LFUS); (B) Experimental process of in vivo PDT under the guidance of CEUS imaging,
followed by ultrasound targeted microbubble destruction (UTMD). (Reprinted with permission from reference [22])
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furthering the applications
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melanoma
well as other promising
contrast agents
for
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targetedultrasound
microbubble
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(Reprinted
with permission
from
(Fig. 6 and 7) [23].
imaging and therapy for prostate cancer.
nce [22])
Lymph Nodes
The utility of peri-tumoral injection of microbubbles
has been established to identify sentinel lymph
nodes but overall sensitivities for predicting tumor
involvement have been poor. Nam et al. explored
sentinel lymph nodes in metastatic melanoma using a
dual-targeted molecular ultrasound agent. Microbubbles
were conjugated with ανβ3 -integrin and P-selectin
antibodies. Following peri-tumoral injection of
Sonazoid in a swine melanoma model, sentinel lymph
nodes were identified using lymphosonography. After
clearance of Sonazoid within the node, intravascular
AUDT 2019;03:062–075

Colon
Colon cancer is another disease where molecular
ultrasound has proved beneficial, especially with the
use of BR55 and molecular targets such as VEGFR2.
Hackl explored detection of liver metastasis of colorectal
cancer with BR55 contrast agent targeting VEGFR2 in
mice. With the use of BR55, smaller lesions were more
accurately detected and can be used to monitor hepatic
metastasis of colon cancer [24].
More recently, studies have shown advancements
in monitoring therapy and angiogenesis by targeting
VEGFR2. After regorafenib therapy, tumor perfusion
065
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was assessed using VEGFR2 binding in one study. Under
therapy, tumor perfusion and microbubble binding were
reduced, showing response to therapy [25]. Similarly,
Pre    

5 s after injection

two other studies using 3D-ultrasound imaging of
microbubbles targeting VEGFR2 showed decreased
VEGFR2 expression after treatment [26,27].

10 s after injection

LFUS exposure

After LFUS

A
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PGL-MBs+LFUS

PGL-MBs only

Pre      30 min       1 h        2 h       6 h       24 h

Low

B
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PGL-MBs+
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PGL-MBs
only
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6.0×107
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Heart Liver Spleen Lung Kidneys Tumor

D

Figure 5 In vivo CEUS and fluorescence imaging in a subcutaneous PC-3 tumor model. (A) In vivo CEUS in a subcutaneous PC-3 tumor model. CEUS
imaging of the tumor site before (pre) and after intravenous administration (i.v.) of PGL-MBs; (B) Fluorescence imaging in vivo at different time points
after intravenous administration of PGL-MBs, with or without LFUS (400 kPa, 3 min) exposure. Tumors are circled with yellow dashed lines; (C) Images
of organs excised at 24 h after injection. Organs of tumor-bearing mice without PGL-MBs injection were excised as negative controls; (D) Quantitative
analysis of fluorescence intensity for the excised organs (n = 3). (Reprinted with permission from reference [22])
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to differentiate the severity of disease by detecting pixel
reference
[22])
contrast density. VEGF expression was increased in mice
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further to monitor inflammatory changes after radiation
therapy [29].
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A

B

Figure 6 Malignant sentinel lymph node (arrows) in swine tumor
model. (A) Contrast enhanced ultrasound image of the node with targeted
microbubbles shows diffuse (42%) enhancement. (B) B-mode ultrasound
image of the heterogenous node.

imaging and difficulties acquiring suitable ultrasound
images in the lung. However, CEUS does have some
utility in small cell lung carcinoma as studied by Wang.
In this study, nanobubbles were loaded with anti-progastrin releasing peptide (proGRP) antibody that target
H446 cell line of small cell carcinoma and resulted in
high binding affinity of the nanobubbles to the target
cells [32]. Likely the future of molecular ultrasound in
lung cancer will be focused on treatment delivery and
future studies should focus on drug delivery as it has
shown to be successful in the above study.

A

Figure 7 Benign lymph node (arrows) in swine model. (A) Contrast
enhanced ultrasound image shows no retention of targeted microbubbles in
the node; (B) B-mode ultrasound demonstrates homogenous lymph node,
likely representing a normal lymph node.

Molecular ultrasound in colon cancer has a wide
application from detecting colon cancer to assessing
changes after colon cancer treatment. Future studies can
utilize BR55 and other anti-angiogenesis targets to target
therapy.

Liver
There are two recent studies in the literature
regarding oncologic applications of molecular
ultrasound in the liver. One study investigated endoglin
targeted microbubbles in evaluation of angiogenesis in
hepatoblastoma, which showed increased enhancement
in the endoglin targeted cells [30] (Fig. 8). Another study
explored VEGFR2 expression using BR55 contrast agent
to evaluate therapy response in hepatocellular carcinoma
and CEUS was able to detect decreased VEGFR2
expression after treatment [31]. We see similar themes as
other organs in the liver with endovascular targets as the
mainstay of investigation and showing promise as targets
for evaluation and treatment of neoplasms.
Lung
Few studies in the literature explore CEUS in lung
pathology due to the predominance of PET-CT and MRI
AUDT 2019;03:062–075

B

B
3
ΔTE (a.u)

A

**

2
1
0

C
Isotype    Target

Figure 8 Isotype and endoglin-targeted ultrasound molecular imaging
of a nude mouse with subcutaneous HB. (A) Intensity graph for the traced
regions of interest prior to and after the destruction pulse (pink region). The
region on the left of the column is prior to destruction, and on the right of it
is after destruction. The change in intensity following the destruction pulse is
an index of the amount of specific binding. The linearized signal prior to the
destruction pulse represents bound and circulating microbubbles (MB) and
tissue signal. The linearized signal after the destruction pulse corresponds
to the MB that were still in circulation and to any residual tissue-echoes,
and does not represent the binding process. The ΔTE was computed by
subtracting the mean intensity detected after the destructive pulse from that
prior to the destructive pulse; (B) Parametric imaging. The scale bar of ΔTE
is on the right corner of the map; (C) ΔTE of isotype and endoglin-targeted
MB. ΔTE=TEfd - TEpd. n=4; **P < 0.001. TE, targeted enhancement; ΔTE,
differential TE; fd, following destruction; pd, prior to destruction; MB,
microbubbles. (Reprinted with permission from reference [30])

Pancreas
A recent review article on molecular imaging in
pancreatic adenocarcinoma reviewed multiple contrast
agents. Molecular CEUS has not been established as a
diagnostic tool in pancreatic adenocarcinoma but has
been established as a potential modality with increased
sensitivity and specificity compared to CT. Molecular
ultrasound targeting angiogenesis such as with VEGFR2
067
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and Thy-1 are currently being explored and have
diagnostic potential [33]. Foygel initially identified Thy1
as a marker for pancreatic adenocarcinoma [33]. AbouElkacem further explored Thy-1 targeted microbubbles in
detecting pancreatic adenocarcinoma by creating a novel
ligand that is more specific to the target tissue and better
penetrating (Thy1-scFv) [34]. Thy1 appears to be the
leading target for investigation currently and may prove to
be a potential early diagnostic and therapeutic target.

Brain
A recent study explored molecular imaging in
glioblastoma. Endoglin (CD105) targeted microbubbles
were used to detect attachment numbers of endolin which
correlated well with IHC. This study shows promise in
using molecular ultrasound to assess angiogenesis in
glioblastoma [35]. However, to date brain tumors remain
a relatively unexplored area with field of molecular

ultrasound.

Ovarian
The first human trial of molecular imaging agent in
patients with ovarian cancer was performed with BR55
targeting KDR which matched well with IHC [8]. Due to
potential instability of ligand-conjugated contrast agents,
Yang et al. combined fluorescent dye, NIRF IR-780
iodide, which can target tumors, to nanobubbles. This
new targeting agent successfully accumulated at female
tumor cells (ovarian and breast) [36]. Gao investigated
targeting CA-125 in ovarian epithelial carcinoma.
Targeted nanobubbles showed tumor accumulation, more
intense signal, and longer retention [37] (Fig. 9). Since
BR55 is the only targeted microbubble to make it to
clinical trials to date but shown limited specificity, future
microbubble iterations could include drug therapy with
tumor specific targets such as CA-125.

Figure 9 Ultrasound contrast agents able to target a molecular signature on the surface of cancer cells could be a promising strategy for improved cancer
detection. The diagram demonstrates application of CA-125-targeted echogenic lipid and surfactant-stabilized nanobubbles (smaller than 200 nm mean
hydrodynamic diameter) for targeting CA-125 positive OVCAR-3 tumors in mice. Targeted or non-targeted nanobubbles were injected into mice (via tail vein)
bearing either CA-125 positive or negative flank ovarian tumors. Tumors were imaged with contrast harmonic imaging at 12 MHz, and time–intensity curves
and histology were utilized to compare tumor distribution and pharmacokinetics of the contrast agents. (Reprinted with permission from reference [37])

Figure 9 Ultrasound contrast agents able to target a molecular signature on the surface of cancer cells
could be a promising strategy for improved cancer detection. The diagram demonstrated application of
CA-125-targeted
echogenic lipid and surfactant-stabilized
(smaller
than
200 nm[40].
mean
agentnanobubbles
promising to assess
response
to therapy
Other applications
hydrodynamic
diameter)
for applications
targeting CA-125
positive OVCAR-3 tumors in mice. Targeted or nonThere are
a few other
of molecular
ultrasound
in the literature
nonspecific
to an (via
organtail vein)
targeted
nanobubbles
were injected
into mice
bearing either
CA-125 positive or negative
Cardiovascular
Applications
system.
Microbubbles
targeted
to
tissue
factor
were
flank ovarian tumors. Tumors were imaged with contrast harmonic imaging at 12 MHz, and time–
foundcurves
to be and
helpful
in quantifying
tumor to
burden,
intensity
histology
were utilized
compareAngiogenesis
tumor distribution and pharmacokinetics of the
providing an additional method of cancer assessment
The evaluation of angiogenesis encompasses two
contrast
agents. (Reprinted with permission from reference
[37])
and may be able to detect early, small tumors [38]. In
another study, nucleolin targeted microbubbles were
investigated and found to accumulate in the nucleolin
cell line more than nontargeted microbubbles [39]. Zhou
et al. explored Annexin V conjugated nanobubbles in
assessing apoptosis. These targeted agents were unique
in that they were easily able to go to tumor vasculature
and accumulate at apoptotic cells, making this contrast
068

main areas: oncology and cardiology. Although some
angiogenesis studies were discussed in the ‘oncology’
section, many studies in the literature were more
focused on generalized angiogenesis. Most cardiology
applications involve evaluating angiogenesis to evaluate
risk for atherosclerosis development. An earlier review
of literature discussed integrin targeted and growth factor
targeted contrast agents which are the current mainstay
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of investigation [41].
Two recent studies in the literature investigated integrin
and growth factor targeted contrast agents including
VEGF and αvβ3. Wang et al. investigated VEGF targeted
microbubbles and found them to be a useful method
for evaluating tumor angiogenesis [42]. Daeichin et al.
investigated αvβ3 targeted microbubbles and found that
expression was increased in atherosclerotic lesions [43].
Tumor angiogenesis is the most common application
of endothelium targeted contrast agents. Three recent
studies regarding integrin targeted microbubbles
investigated tumor angiogenesis. Yan et al. incorporated
iRGD-lipopeptides into the αvβ3 targeted microbubbles
to increase tumor penetrability and found that this
method increased signal intensity and contrast
enhancement in mice with breast tumors [44]. Otani et
al. created an easier to prepare lactadherin containing
microbubble targeted to avb3-integrin and found that
it accumulated in mice bearing tumors [45]. Hu et al.
created an arginine-glycine-aspartate (RGD)-targeted
microbubble to assess avb3 expression and angiogenesis.
Laryngeal carcinoma (Hep-2) xenografts were used
and signal was significantly increased in smaller
tumors which is consistent with expected changes in
angiogenesis in tumors [46] (Fig. 10).

therapy in mice with colorectal carcinoma and found
that it could detect decreased tumor burden by detecting
decreased VEGFR2 [47]. Since neuropilin peptides
have been shown to internalize in cells, Zhang et a;.
evaluated the effectiveness of two neuropilin-1 targeted
peptides in determining tumor angiogenesis. This
study found that a new agent, CRPPR, can bind to cells
that express neuropilin and can be useful in imaging
angiogenesis [48].

Atherosclerosis
Most recent molecular ultrasound studies in the
literature investigating atherosclerosis have focused
on targets on platelets for diagnostic and therapeutic
applications or assessing inflammation as a risk factor
for early atherosclerosis development.
Recent studies have explored contrast agents targeted
to glycoproteins on platelets to monitor atherosclerosis
progression. Maier et al. studied microbubbles targeted
to antibody to ligand induced binding site (LIBS)
of glycoprotein IIb/IIIa of the platelet in carotid
endarterectomy specimens. Signal enhancement was
significantly higher after administration of the LIBSlinked microbubble [49]. Two earlier studies also
explored glycoprotein targeted microbubbles. Shengcun
studied microbubbles targeted to glycoprotein IIb/IIIa
and found that targeting this glycoprotein specifically
was associated with more vulnerable plaques, which can
help prevent acute cardiac events if therapy is started
early [50]. Metzger et al. found that glycoprotein-IV
targeted microbubbles were diagnostic and therapeutic.
After accumulation of the contrast agent was detected,
A
high frequency ultrasound was able to interfere with
and disrupt plaques which may decrease progression of
atherosclerosis [51].
Other studies have linked markers of vessel
inflammation to progression of atherosclerosis, especially
small peptides like VCAM-1. Sun et al. used VCAM1 targeted microbubbles to assess progression of
B
atherosclerosis and found that it was a good marker for
progression since enhancement increased as plaques
increased [52]. Moccetti et al. studied microbubbles targeted
to multiple endothelium markers and found that VCAM1 and von Willebrand factor had the strongest signal
intensity [53]. Another study assessed VCAM-1 and other
C
small peptide endothelial markers as indicators of highrisk plaques and found that VCAM-1 showed the highest
Figure 10 The region of interest (ROI) was drawn on the SK-OV-3 tumors
manually so as not to encompass the areas with excessive signal intensity or
correlation with high-risk atherosclerotic disease [54].
perfusion defects. (Reprinted with permission from reference [45])
The region of interest (ROI) was drawn on the SK-OV-3 tumors manually so asTwo
not torelatively unique applications were investigated
in permission
the recent from
literature. Curaj et al. studied detection of
the areas with excessive signal intensity or perfusion defects. (Reprinted with
A few new studies explored treatment response and
turbulent blood flow leading to endothelial dysfunction
45])
new contrast agents. Payen assessed the effectiveness of
using junctional adhesion molecule A (JAM-A) targeted
BR55 targeting VEGFR2 in assessing anti-angiogenesis
microbubbles and found that CEUS was able to
AUDT 2019;03:062–075
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detect higher JAM-A expression at the site with more
turbulent flow which can indicate a higher risk area for
atherosclerotic disease [55]. Another study assessed
atherosclerosis treatment response to antioxidant
therapy by using P-selectin, von Willebrand factor,
and glycoprotein Iba targeted microbubbles. Molecular
ultrasound was able to detect response to therapy via
decreased signal in all three ligands [56].
The most significant development recently has been
the ability to determine atherosclerotic plaques that
are at higher risk of rupture and detecting early risk of
plaque development by assessing inflammation. These
findings will need to be reproduced in human studies to
ultimately help identify high risk individuals, provide
early treatment, and prevent acute cardiac events.

Inflammation
Molecular ultrasound applications to detect
inflammation are varied from vessel inflammation and
injury to myocardial inflammation. Rix et al. studied
avB3-integrin expression after vessel injury during
endovascular interventions which can indicate injury
and inflammation. This study found upregulation of
the specific integrin in injured vessels and improved to
baseline as vessel healed [57]. Targeting this integrin can
help assess early vessel injury after interventions and
help guide early treatment.
Two studies explored abdominal aorta inflammation.
A study by Wang et al. successfully used P-selectin and
VCAM-1 targeted microbubbles to assess inflammation
in mice abdominal aorta, an early indicator for
development of atherosclerosis [58]. Wu et al. compared
the use of P-selectin targeted microbubbles versus dualtargeted microbubbles with the addition of PAA-sialyl
Lewis-X targeting and found that P-selectin targeted
microbubbles had better adhesive efficacy under all
shear stress conditions compared to the dual targeted
microbubbles [59].
Myocardial inflammation caused by myocarditis and
infarction was also recently studied. Leng et al. studied
detection of recent myocardial ischemia using E-selectin
targeted microbubbles since E-selectin is known to
upregulate after myocardial ischemia. E-selectin was
found to be an effective target to identify recent ischemia
using echocardiography [60]. Steinl et al. evaluated
detection of myocarditis using CD4 T-cell-targeted
microbubbles to detect an inflammatory response and
found that molecular ultrasound correlated well with the
severity of inflammation [61].
Using molecular ultrasound to evaluate arterial
inflammation is a promising modality to evaluate risk
for atherosclerosis development. The studies exploring
evaluation for myocardial ischemic changes indicate a
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potential non-invasive and potentially more accurate
method of evaluating for ischemic cardiomyopathy in the
future.

Venous Thrombosis
One recent study in the literature aimed to distinguish
acute deep vein thrombosis (DVT) from chronic
DVT by detecting thrombin, a marker for acute DVT.
Perfluorobutane-filled (PFB-filled) microbubbles with
thrombin-sensitive activatable cell-penetrating peptides
(ACPPs) were created. In this in vitro study, the contrast
agent was able to detect thrombin successfully while
retaining 91.7% of the signal. This contrast agent could
potentially be used to more accurately distinguish acute
from chronic thrombus which is currently a challenge
when using non-molecular ultrasound [62].
Renal Applications
Two recent studies explored molecular ultrasound
applications in the kidneys. Hoyt’s group investigated
tissue injury due to acute kidney injury. P-selectin
targeted and VCAM-1 targeted microbubbles were used
to assess inflammation and P-selectin was found to be
more sensitive but both molecular targets correlated
with IHC [63]. Rojas et al. assessed response to antiangiogenic therapy in mice with clear-cell renal cell
cancer by using VEGF targeted microbubbles and found
that in 92% of treatments, molecular ultrasound was able
to detect response [64] (Fig. 11). These studies indicate
that molecular ultrasound may be a more accurate
assessment of disease processes in the kidneys.
Non-Oncologic Liver Applications
Non-oncologic applications of molecular ultrasound
imaging of the liver are focused on evaluating fibrosis
and liver injury. Although other imaging molecular
imaging modalities including PET have been used
to stage liver fibrosis, molecular ultrasound has not
been explored as extensively. Xuan et al. conjugated
nanoparticles with cyclic arginine-glycine-aspartic acid
(cRGD) to target avB3 which was able to distinguish
stages of liver fibrosis [65].
Two recent studies in the literature evaluated
ischemia-reperfusion liver injury (IRI). Qiu used
ICAM-1 targeted microbubbles to determine IRI and to
determine the severity of IRI [66] (Figure 12 and 13).
Xie et al. targeted the same molecule in a similar study
and found that targeting ICAM-1 was specific to IRI [67].
These two applications of molecular ultrasound in
the liver are significant in that a less invasive method
without radiation or nephrotoxic contrast agent exposure
would be a preferred and more accurate modality over
CT or MRI in the future.
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A                    B                    C
Figure 11 Molecular ultrasound imaging with VEGF targeted microbubbles detected response of anti-angiogenic therapy in mice with clear-cell cancer.
Method for obtaining anechoic regions in a peak intensity image (A). The green dots outline the tumor. The image is blurred using a Gaussian filter to
eliminate dark areas in speckle (B). The regions below a predetermined intensity threshold are selected as anechoic (C). Note: these are single frames in a
3D volume, so the process will be performed for each slice in the volume. (Reprinted with permission from reference [64])
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Figure 12 Representative targeted ultrasound (US) images for intracellular adhension molecule-1 (ICAM-1) and normalized intensity difference (NID)
in each group. (A) Representative targeted ultrasound (US) images of ICAM-1–targeted microbubbles (MBICAM-1) and control microbubbles (MBCON)
in ischemia–reperfusion injury (IRI) rats and control rats. US signal after MBICAM-1 in IRI liver was substantially higher than that in control liver and
was significantly higher compared with MBCON in IRI liver and normal liver; (B) The normalized intensity differences (NIDs) were calculated as the ratio
of subtraction using the destruction–replenishment method (n = 3, *P = 0.048, IRI group compared with control group after MBICAM-1 administration).
(Reprinted with permission from reference [66])
ICAM‐1

Figure 12 Representative targeted ultrasound (US) images for intracellular adhension molecule‐1
(ICAM‐1) and normalized intensity difference (NID) in each group. (A) Representative targeted
ultrasound (US) images of ICAM‐1–targeted microbubbles (MB
) and control microbubbles
(MBCON) in ischemia–reperfusion injury (IRI) rats and control rats. US signal after
High MBICAM‐1 in IRI liver
was substantially higher than that in control liver and was significantly higher compared with MBCON in
IRI liver and normal liver. (B) The normalized intensity differences (NIDs) were calculated as the ratio of
subtraction using the destruction–replenishment method (n = 3, *p = 0.048, IRI group compared with
control group after MBICAM‐1 administration). (Reprinted with permission from reference [66])
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Figure 13 Representative targeted ultrasound (US) images evaluating different degrees of ischemia–reperfusion injury (IRI). Targeted US imaging signal
was weakest in the control liver (A) and strongest in the moderate to severe IRI liver (C) compared with that in the mild IRI liver (B); (D) The normalized
intensity difference (NID) in each group. (*P < 0.001 mild IRI group vs control group, #P = 0.002) moderate to severe IRI group vs mild IRI group, &P < 0.001
moderate to severe IRI group vs control group). (Reprinted with permission from reference [66])
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Pediatric Applications
Much of the same applications in adults can be
applied to the pediatric population. Kiessling’s review
outlines the preclinical studies of molecular ultrasound
in different organ systems and mentions some potential
applications in the pediatric population including
monitoring antiangiogenic therapy, detecting arthritis,
organ transplantation rejection monitoring, guiding
biopsies, identifying ischemic lesions in the brain,
and drug delivery [68]. However, to date few research
reports have differentiated between adult and pediatric
malignancies.
Drug Delivery Applications
Drug delivery is a promising application of molecular
imaging and extensive research has been conducted
recently in multiple fields, especially oncology.
Examples of targeted contrast agents providing gene

therapy and chemotherapy for prostate cancer include
nanobubbles targeted towards A10-3.2 aptamer for gene
therapy [69] and chemotherapy [70]. This method was
possible by ultrasound-guided contrast agent destruction
at the target site to mediate drug or gene therapy delivery.
Luo et al. studied a dual-targeted (folate and cRGD
peptide) microbubble complex to provide chemotherapy
in tumor tissues with specificity and significant
accumulation [71] (Fig. 14).
In brain cancer, Chang et al. created VEGFR2targeted microbubbles for gene therapy and found that
using transcranial focused ultrasound, gene therapy
effectively targeted brain tumor tissue without affecting
normal brain tissue when using the specific contrast
agent [72]. Molecular ultrasound mediated gene therapy
has also been proven successful in mice models with
ovarian cancer [73].
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Figure 14 Schematic illustration of the image and analysis protocol (A). After monitoring for 4 min, targeted MBs were considered to adhere to the tumor
site firmly. Blank MBs or DPMC were destroyed by the Flash mode of the ultrasound system. The process was monitored, starting from injection to at least
30 s after Flash destruction. The video intensity (VI) from adherent MBs (Targeted VI) was assessed by calculating the average pre- and post-destruction
VI, and subtracting average post- from pre-destruction intensity. Ultrasound molecular images representing intensity from adherent blank MBs or DPMC
displayed as color maps overlaid on B-mode images (B). Yellow line represents the region of interest (ROI). Image signals are quantitatively presented
(***P<0.001) (C). (Reprinted with permission from reference [71])
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may be the mainstay method of targeted drug therapy in
the future.

Conclusions

Ultrasound molecular imaging has shown to be a
romising modality particularly in the fields of oncology
and cardiology. The most well-studied and currently only
contrast agent to be translated to clinical trials is BR55
which is used to evaluate angiogenesis in malignancies.
The most promising future applications continue to
be drug delivery mechanisms and the early prediction
of certain diseases such as atherosclerosis and early
cancer development to guide early treatment to improve
outcomes. However, to date much of the applications of
ultrasound molecular imaging are in the early stages of
research in animal models and need more study to gain
clinical relevance.
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